<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058157</url>
  </required_header>
  <id_info>
    <org_study_id>1803NR</org_study_id>
    <nct_id>NCT05058157</nct_id>
  </id_info>
  <brief_title>Ketone Plasma Kinetics After Oral Intake of Different Ketogenic Formulae</brief_title>
  <official_title>Ketone Plasma Kinetics After Oral Intake of Different Ketogenic Formulae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project aims at evaluating the effect of various ketone precursors and their&#xD;
      formulations on blood ketone level after oral intake. Evaluation of the GI tolerability of&#xD;
      the various formula will be also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each testing cycle design will be either a complete or partial cross-over.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ketone Plasma Kinetics After Oral Intake of Different Ketogenic Formulae</measure>
    <time_frame>0 (baseline) to 4 hours after products consumption</time_frame>
    <description>Incremental area under the curve of total blood ketones</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Men and Women</condition>
  <arm_group>
    <arm_group_label>Ketone Precursor Formula 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formula 1 (in each cycle, up to 4 formula will be tested) Ketone precursors formula (powder to reconstitute in drinking water, or in a ready-to-drink format).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketone Precursor Formula 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketone Precursor Formula 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketone Precursor Formula 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketone precursors formula (powder to Reconstitute in drinking water, or in a ready-to-drink format), or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>different ketogenic formulae</intervention_name>
    <description>The research product may be in a form of powder to reconstitute or in a ready-to-drink format.</description>
    <arm_group_label>Ketone Precursor Formula 1</arm_group_label>
    <arm_group_label>Ketone Precursor Formula 2</arm_group_label>
    <arm_group_label>Ketone Precursor Formula 3</arm_group_label>
    <arm_group_label>Ketone Precursor Formula 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women, based on the screening visit and medical history,&#xD;
&#xD;
          -  BMI in the normal and overweight range 18.5 ≤ BMI ≤ 27;&#xD;
&#xD;
          -  Able to understand and sign informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medication possibly impacting the postprandial glucose and insulin response (based&#xD;
             on anamnesis),&#xD;
&#xD;
          -  Any medication impacting dietary fat absorption and metabolism,&#xD;
&#xD;
          -  Pregnancy (on anamnesis) and/or lactation,&#xD;
&#xD;
          -  Known food allergy and food intolerance,&#xD;
&#xD;
          -  Individuals undergoing either dietary or exercise mediated weight loss program&#xD;
             prescribed by a health care professional,&#xD;
&#xD;
          -  Individuals under ketogenic diets, or taking regular ketones products,&#xD;
&#xD;
          -  Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols,&#xD;
             1 dl of red or white wine, or 3 dl of bier,&#xD;
&#xD;
          -  Having given blood within the last month, or willing to make a blood donation until&#xD;
             one month following the end of the study,&#xD;
&#xD;
          -  Family or hierarchical relationships with Clinical Innovation Lab at Nestlé Research,&#xD;
             Lausanne, Switzerland,&#xD;
&#xD;
          -  Volunteer who cannot be expected to comply with the protocol,&#xD;
&#xD;
          -  Smokers unable to stop for the day of the visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernard PhD Cuenoud</last_name>
    <phone>+41 21 924-6533</phone>
    <email>Bernard.Cuenoud@nestle.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie PhD Piccardi</last_name>
    <phone>+41 21 785-9510</phone>
    <email>Nathalie.Piccardi@rdls.nestle.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nestlé Clinical Innovation Lab</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

